simeprevir
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine
More than 11,000 people are diagnosed with head and neck cancers every year in England
Navigating NHS Market Access: Policy Change and Opportunity in England
With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...
Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency
Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...
NICE recommends ALK’s immunotherapy to target underlying cause of hay fever
An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax
NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS
Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK